A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

I-MAT will determine if a six-month treatment regime of Avelumab is well-tolerated and can eliminate residual microscopic cancer cells, thus reducing the risk of the cancer reoccurring and improving the overall outcomes for patients with early-stage Merkel cell carcinoma.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC Trials)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

132

Expected Date of Accrual

June 2024

Trial Chairperson

Dr Wen Xu, Princess Alexandra Hospital, QLD, Australia

Trial Contact

imat@masc.org.au

Related Post

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

Grant for PRIME-Lung trial
10 June, 2025

MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer

LATEST NEWS: 10 JUNE 2025 A trial of a